USA flag logo/image

An Official Website of the United States Government

A new technology for functional solubilization of kinases

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44GM083486
Solicitation Year:
2011
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA10-050
Small Business Information
Molecular Kinetics Inc
6201 La Pas Trail Suite 160 Indianapolis, IN 46268-4869
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: A new technology for functional solubilization of kinases
Agency: HHS
Contract: 2R44GM083486-02
Award Amount: $904,883.00
 

Abstract:

DESCRIPTION (provided by applicant): Protein kinases are essential enzymes that function primarily as components of signaling pathways, regulating cellular responses such as division, growth, differentiation, and death. Abnormalities in these signaling pathways can lead to wide- ranging and devastating pathological conditions. For these reasons, protein kinases are important targets for drug development as evidenced by the ~20 kinase inhibitor therapeutics that have been FDA approved or are in late-stage development. Unfortunately, functional analyses of protein kinases are often complicated by poor solubility. Although several approaches have been developed for improving recombinant protein solubility, many kinases remain recalcitrant to these solubilization techniques. Therefore, there is a need for novel kinase-specific solutions for the improvement of solubility. This project is for the development of a novel solubilization approach based on the translational-fusion of protein kinases to highly flexible,non-aggregating polypeptide chains, known as entropic bristles (EBs). The bristles are unique synthetic sequences that have been optimized to improve protein kinase solubility. The Phase I extension period of this project successfully demonstrated that a prototype AquoKin expression vector facilitated the soluble expression of eight out of eight protein kinases. Moreover, the EBs did not adversely affect the catalytic activity of the kinase toward a substrate. During Phase II of this project, we will develop, optimize, and validate commercial products and applications that are based on the EB-based kinase solubility-enhancing vectors, brand named AquoKin . The potential benefit of this project to the scientific research community and society as a whole is substantial. Kinases are not only vital to maintenance of normal cellular function, but are also pervasively involved with human pathologies and disease. The AquoKin line of products will make more protein kinases accessible for research applications and do so in the most cost-effective expression system. From a human health standpoint, this project has the potential to facilitate drug discovery efforts that target protein kinases. Moreover, the anticipated AquoKin products will aid basic research effortson protein kinases from multiple organisms by lowering research costs. PUBLIC HEALTH RELEVANCE: Protein kinases are important enzymes that regulate cell signaling. Dysregulateion of kinases is often causal for a myriad of pathological conditions andare important drug targets. The purpose of this project is to develop a set of vectors that facilitate the soluble expression of active kinases recalcitrant to other solubilization technologies thereby aiding kinase research efforts.

Principal Investigator:

Carrie H. Croy
317-280-8737
ccroy@molecularkinetics.com

Business Contact:

Ya Y. J
317-280-8737
main@molecularkinetics.com
Small Business Information at Submission:

MOLECULAR KINETICS, INC.
6201 La Pas Trail SUITE 160 INDIANAPOLIS, IN 46268-

EIN/Tax ID: 191136611
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No